Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.

Abstract:

:The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinical efficacy was determined using the Positive and Negative Syndrome Scale (PANSS), and side-effects with the Treatment Emergent Symptom Scale (TESS). Risperidone produced a mean 39.8 +/- 24.1% reduction in total PANSS score compared to a mean 28.3 + 19.4% reduction in the haloperidol group (P < 0.05). Analysis of changes for the three subscores of the PANSS revealed that the general psychopathology and negative subscores were significantly improved in the risperidone group compared to the haloperidol group. As for the side-effects, the risperidone group showed a significantly lower TESS total score, as well as nervous system symptoms subscore and cardiovascular symptoms subscore, compared to the haloperidol group. Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol.

authors

Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

doi

10.1097/00004850-200111000-00002

subject

Has Abstract

pub_date

2001-11-01 00:00:00

pages

325-30

issue

6

eissn

0268-1315

issn

1473-5857

journal_volume

16

pub_type

临床试验,杂志文章,随机对照试验
  • Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.

    abstract::Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment. At follow-up most patients (74%) did not suffer from panic attacks at all. In the beginnin...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300820-00006

    authors: Lepola UM,Rimón RH,Riekkinen PJ

    更新日期:1993-07-01 00:00:00

  • The relationship between social phobia and avoidant personality disorder: workshop report 3.

    abstract::Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

    journal_title:International clinical psychopharmacology

    pub_type:

    doi:

    authors: Dahl AA

    更新日期:1996-06-01 00:00:00

  • Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia.

    abstract::Although the effects of atypical antipsychotics with regard to improving neurocognitive function are not sufficiently high. The present study applied an atypical antipsychotic monotherapy for patients with acute schizophrenia to (1) examine the percentage of patients who respond well to this treatment, (2) explore the...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000293

    authors: Hori H,Yoshimura R,Katsuki A,Atake K

    更新日期:2020-03-01 00:00:00

  • Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?

    abstract::The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Ashford JJ

    更新日期:1995-01-01 00:00:00

  • Novel antipsychotics and negative symptoms.

    abstract::Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803003-00008

    authors: Möller HJ

    更新日期:1998-03-01 00:00:00

  • Prediction of response to acute neuroleptic treatment in schizophrenia.

    abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199605002-00008

    authors: Gaebel W

    更新日期:1996-05-01 00:00:00

  • Is amisulpride an 'atypical' atypical antipsychotic agent?

    abstract::Amisulpride is a novel antipsychotic with a pharmacological and clinical profile that differs from that of other atypical agents. Amisulpride is highly selective for dopamine D2/D3 receptor subtypes located in the limbic region, which is highly predictive of potent antipsychotic activity with a low potential to cause ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Lecrubier Y

    更新日期:2000-12-01 00:00:00

  • Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

    abstract::Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

    更新日期:1996-06-01 00:00:00

  • Therapeutic receptor-blocking concentrations of neuroleptics.

    abstract::The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Seeman P

    更新日期:1995-09-01 00:00:00

  • A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

    abstract::Zopiclone, a cyclopyrrolone with hypnotic properties was compared with temazepam and placebo in the treatment of insomnia. After a week's washout period, suitable subjects were allocated at random to zopiclone 7.5 mg or temazepam 20 mg or placebo for 2 weeks. Measurements of psychomotor function using the Leed's psych...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199007000-00001

    authors: Ngen CC,Hassan R

    更新日期:1990-07-01 00:00:00

  • Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.

    abstract::Sertindole is a novel atypical antipsychotic, which has shown efficacy in the treatment of positive and negative symptoms of schizophrenia in phase II and III studies. Furthermore, these studies have demonstrated tolerability and a favourable side-effect profile. In contrast to classical antipsychotics, sertindole was...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015040-00003

    authors: Pezawas L,Quiner S,Moertl D,Tauscher J,Barnas C,Küfferle B,Wolf R,Kasper S

    更新日期:2000-07-01 00:00:00

  • DIABCARE Quality Network in Europe--a model for quality management in chronic diseases.

    abstract::The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200104003-00002

    authors: Piwernetz K

    更新日期:2001-04-01 00:00:00

  • Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.

    abstract::It has been suggested that the atypical antipsychotic drugs may induce a rapid improvement in individuals with melancholic depression. This might reflect a specific or non-specific effect on mood and other parameters. To examine this issue, ten consecutive patients, for whom olanzapine augmentation was judged a clinic...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200203000-00008

    authors: Parker G

    更新日期:2002-03-01 00:00:00

  • Gender and age differences in the growth hormone response to pyridostigmine.

    abstract::Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199100620-00005

    authors: Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

    更新日期:1991-07-01 00:00:00

  • Clinical utility of milnacipran in comparison with other antidepressants.

    abstract::The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200206001-00006

    authors: Bisserbe JC

    更新日期:2002-06-01 00:00:00

  • Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis.

    abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199805000-00006

    authors: Gadre DV,Talwar V,Gupta HC,Murthy PS

    更新日期:1998-05-01 00:00:00

  • New aspects in the treatment of depression.

    abstract::Because of the limitations in efficacy and safety of the older tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) a number of new approaches have been made in recent years to the treatment of depression to obtain more effective, more rapidly acting, better tolerated and safer drugs. One tactic has...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199206005-00004

    authors: Silverstone T

    更新日期:1992-06-01 00:00:00

  • Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.

    abstract::Sleep disorders, such as insomnia and nightmares, are common problems in post-traumatic stress disorder (PTSD), exert a strong negative influence on the quality of life and are a great challenge for clinical psychiatry. Several studies have reported on the efficacy of drugs for the treatment of PTSD-related sleep diso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200607000-00001

    authors: van Liempt S,Vermetten E,Geuze E,Westenberg HG

    更新日期:2006-07-01 00:00:00

  • Clinical trials of new antipsychotics: a critical appraisal.

    abstract::In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199903000-00012

    authors: Barbui C,Garattini S

    更新日期:1999-03-01 00:00:00

  • Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients.

    abstract::The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. Each patient received 3 mg risperidone twice a day for 28 days. Amitriptyline was coadministered at doses of 50 mg/d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199705000-00004

    authors: Sommers DK,Snyman JR,van Wyk M,Blom MW,Huang ML,Levron JC

    更新日期:1997-05-01 00:00:00

  • Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.

    abstract::This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000218

    authors: Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

    更新日期:2018-07-01 00:00:00

  • The conundrum of depression clinical trials: one size does not fit all.

    abstract::In this paper we review the history of antidepressant (AD) development, since the discovery of imipramine in 1957 to the present day. Through this exploration we will show that the increasing placebo response is likely a red herring and that a higher magnitude of placebo response is not an adequate explanation for AD ...

    journal_title:International clinical psychopharmacology

    pub_type: 历史文章,杂志文章,评审

    doi:10.1097/YIC.0000000000000229

    authors: Khan A,Mar KF,Brown WA

    更新日期:2018-09-01 00:00:00

  • Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam.

    abstract::Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198807000-00003

    authors: Mattila M,Seppala T,Mattila MJ

    更新日期:1988-07-01 00:00:00

  • Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

    abstract::The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study. Paroxetine was used as active control. After 12 weeks of double-blind treatment with agomelatine 25 mg/day or paroxetine 20 mg/day, sustained remitted depress...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.yic.0000137184.64610.c8

    authors: Montgomery SA,Kennedy SH,Burrows GD,Lejoyeux M,Hindmarch I

    更新日期:2004-09-01 00:00:00

  • Carbamazepine in rapid cycling bipolar affective disorder.

    abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198804000-00003

    authors: Joyce PR

    更新日期:1988-04-01 00:00:00

  • Application of an individually predicted dosage of amitriptyline to the treatment of depression.

    abstract::The treatment of depressed patients with a fixed dose of amitriptyline is compared to treatment with an individualized dose calculated by means of a simple pharmacokinetic test. Clinical response and the development of side-effects are compared between the two groups of patients. Although the numbers in the groups wer...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198710000-00003

    authors: Roy D,Dawling S

    更新日期:1987-10-01 00:00:00

  • Do continued antidepressants protect against dementia in patients with severe depressive disorder?

    abstract::Studies on humans show that depressive disorder is associated with an increased risk of developing cognitive dysfunction, and animal studies suggest that antidepressants may have neuroprotective abilities. On the basis of these observations, it was hypothesized that treatment with antidepressants may decrease the risk...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e32834ace0f

    authors: Kessing LV,Forman JL,Andersen PK

    更新日期:2011-11-01 00:00:00

  • A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment.

    abstract::Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000198

    authors: Drago A,Kure Fischer E

    更新日期:2018-01-01 00:00:00

  • Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.

    abstract::Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. I...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/01.yic.0000122861.35081.16

    authors: van Os J,Bossie CA,Lasser RA

    更新日期:2004-07-01 00:00:00

  • Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?

    abstract::Stevens-Johnson syndrome is a severe and potentially life-threatening cutaneous reaction associated with lamotrigine. The incidence of developing Stevens-Johnson syndrome during lamotrigine therapy is low. On the basis of the glutamate and dopamine neuron dysregulation hypothesis in schizophrenia, we propose new strat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000224789.21406.81

    authors: Shen YC,Chen SJ,Lin CC,Chen CH

    更新日期:2007-07-01 00:00:00